Sec Form 4 Filing - Skyline Venture Partners Qualified Purchaser Fund IV L P @ PROTEON THERAPEUTICS INC - 2014-10-27

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Skyline Venture Partners Qualified Purchaser Fund IV L P 2. Issuer Name and Ticker or Trading Symbol PROTEON THERAPEUTICS INC [ PRTO] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director X __ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) 525 UNIVERSITY AVENUE, SUITE 610 3. Date of Earliest Transaction (MM/DD/YY) 10/27/2014 (Street) PALO ALTO, CA94301 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) _____ Form filed by One Reporting Person __ X __ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 10/27/2014 P 200,000 ( 1 ) A $ 10 200,000 D ( 2 ) Common Stock 10/27/2014 C 1,167,208 ( 3 ) ( 4 ) ( 5 ) ( 6 ) ( 7 ) ( 8 ) A 1,367,208 D ( 2 ) Common Stock 10/27/2014 X 121,760 ( 9 ) ( 4 ) A $ 4.6023 ( 9 ) 1,488,968 D ( 2 ) Common Stock 10/27/2014 S( 9 ) 56,038 ( 9 ) ( 4 ) D $ 10 1,432,930 D ( 2 )

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Series A Convertible Preferred Stock ( 3 ) 10/27/2014 C 5,000,000 ( 3 ) ( 3 ) Common Stock 375,608 ( 4 ) $ 0 0 D ( 2 ) Series A-1 Convertible Preferred Stock ( 5 ) 10/27/2014 C 2,341,664 ( 5 ) ( 5 ) Common Stock 179,903 ( 4 ) $ 0 0 D ( 2 ) Series B Convertible Preferred Stock ( 6 ) 10/27/2014 C 2,173,913 ( 6 ) ( 6 ) Common Stock 168,680 ( 4 ) $ 0 0 D ( 2 ) Series C Convertible Preferred Stock ( 7 ) 10/27/2014 C 2,436,437 ( 7 ) ( 7 ) Common Stock 189,049 ( 4 ) $ 0 0 D ( 2 ) Series D Convertible Preferred Stock ( 8 ) 10/27/2014 C 3,932,747 ( 8 ) ( 8 ) Common Stock 247,810 ( 4 ) ( 8 ) $ 0 0 D ( 2 ) Warrants (Right to Buy) $ 4.6023 10/27/2014 X 121,760 ( 9 ) ( 9 ) Common Stock 121,760 ( 4 ) $ 0 0 D ( 2 ) Option (Right to Purchase) ( 10 ) 10/27/2014 J 1,389,064 ( 10 ) ( 10 ) Series D Convertible Preferred Stock 87,527 ( 4 ) ( 10 ) 0 D ( 2 )

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Skyline Venture Partners Qualified Purchaser Fund IV L P 525 UNIVERSITY AVENUE, SUITE 610 PALO ALTO, CA94301 X Skyline Venture Management IV, LLC 525 UNIVERSITY AVENUE, SUITE 610 PALO ALTO, CA94301 X Freund John Gordon 525 UNIVERSITY AVENUE, SUITE 610 PALO ALTO, CA94301 X KANEKO YASUNORI 525 UNIVERSITY AVENUE, SUITE 610 PALO ALTO, CA94301 X Signatures /s/ Karensa Kenny as attorney-in-fact Skyline Venture Partners Qualified Purchaser Fund IV L.P. 10/29/2014 Signature of Reporting Person Date /s/ Karensa Kenny as attorney-in-fact Skyline Venture Manage ment IV, LLC 10/29/2014 Signature of Reporting Person Date /s/ Karensa Kenny as attorney-in-fact John Gordon Freund 10/29/2014 Signature of Reporting Person Date /s/ Karensa Kenny as attorney-in-fact Yasunori Kaneko 10/29/2014 Signature of Reporting Person Date

Explanation of Responses:

( 1 )These shares were purchased in connection with the Issuer's initial public offering of Common Stock. ( 2 )The shares are held by Skyline Venture Partners Qualified Purchaser Fund IV L.P. ("Skyline"). John G. Freund, M.D. and Yasunori Kaneko, M.D. are Managing Directors of Skyline Venture Management IV, LLC, the sole general partner of Skyline, and may be deemed to share voting and dispositive power over the shares held by Skyline. Each of Drs. Freund and Kaneko disclaim beneficial ownership of such shares, except to the extent of their pecuniary interest therein. ( 3 )Upon the closing of the Issuer's initial public offering, each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1-for-1.19 basis without payment of further consideration and with no expiration date. ( 4 )Reflects a 1-for-15.87 reverse stock split effected on October 6, 2014. ( 5 )Upon the closing of the Issuer's initial public offering, each share of Series A-1 Convertible Preferred Stock automatically converted into Common Stock on a 1-for-1.22 basis without payment of further consideration and has no expiration date. ( 6 )Upon the closing of the Issuer's initial public offering, each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1-for-1.23 basis without payment of further consideration and has no expiration date. ( 7 )Upon the closing of the Issuer's initial public offering, each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1-for-1.23 basis without payment of further consideration and has no expiration date. ( 8 )Upon the closing of the Issuer's initial public offering, each share of Series D Convertible Preferred Stock automatically converted into Common Stock on a one-for-one basis (without payment of further consideration and with no expiration date) plus an additional 6,158 incremental shares as a result of an adjustment as provided for in the Company's certificate of incorporation. ( 9 )Upon the closing the Issuer's initial public offering, Skyline exercised their warrants to purchase common stock on a net issue basis resulting in the net issuance of 65,722 shares of common stock. ( 10 )Skyline had a right to purchase shares of Series D Convertible Preferred Stock under the Series D Purchase Agreement at a price of $0.588656, which right to purchase ceased to be exercisable upon the initial filing of the Issuer's registration statement for its initial public offering, and terminated upon the completion of the Issuer's initial public offering of Common Stock. Each share of Series D Preferred Stock issuable upon exercise of the right to purchase would have been convertible into shares of the Issuer's common stock as described in footnote (8) above.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.